Incyte Corporation INCY today announced a global license and
collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the
development and commercialization of SHR-1210, an investigational
anti-PD-1 monoclonal antibody. Under the agreement, Incyte will have the
exclusive development and commercialization rights to SHR-1210
worldwide, with the exception of Mainland China, Hong Kong, Macau, and
Taiwan. SHR-1210 is expected to enter proof-of-concept studies for the
treatment of patients with advanced solid tumors in the coming months.
"The addition of this anti-PD-1 candidate to our early stage portfolio
reinforces our commitment to cancer patients and further diversifies our
clinical development programs," stated Hervé Hoppenot, President and
Chief Executive Officer of Incyte. "We continue to make excellent
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in